Today: 19 April 2026
Diageo share price barely moves as investors wait for Feb results and CEO’s next steps
26 January 2026
1 min read

Diageo share price barely moves as investors wait for Feb results and CEO’s next steps

London, Jan 26, 2026, 09:10 GMT — Regular session

  • Diageo shares were mostly flat in early London trading, following a sluggish finish to last week
  • Investors are eyeing interim results due Feb. 25 for fresh insights on strategy and demand
  • The stock is still far from its 52-week high, adding pressure on management

Diageo (DGE.L) edged up 0.03% to 1,675.5 pence in early Monday trading, just above last Friday’s close of 1,675.0 pence. The shares remain roughly 34% shy of their 52-week peak at 2,535 pence.

It’s crucial since Diageo’s upcoming results arrive in a market that’s lost patience with major consumer players. Investors are eager to see which changes under the new CEO are making an impact and if the demand slump has finally bottomed out.

European shares held steady, as investors stayed cautious following recent tariff concerns and ahead of this week’s U.S. Federal Reserve policy announcement.

Diageo has set expectations low for the year. In an “aide memoire” issued this month, the company reiterated its fiscal 2026 guidance for organic net sales growth — that is, like-for-like — to be flat or slightly negative. The firm pointed to challenges from Chinese white spirits and a softer U.S. consumer market than anticipated. www.diageo.com

The company has also relied on its Accelerate programme, expecting it to drive low- to mid-single-digit organic operating profit growth as cost savings come through.

Sir Dave Lewis, stepping in as CEO on Jan. 1, acknowledged the market is dealing with “some headwinds” but emphasized “significant opportunities” ahead. www.diageo.com

Since Diageo slashed its annual forecast in November, the stock has struggled to stabilize amid softer U.S. sales and a sharp drop in China caused by baijiu’s slump.

China is still a hot topic. Bloomberg reported earlier this month that Diageo is exploring options for its China assets, possibly including a sale. The company declined to comment to Reuters when asked.

Dividends and balance sheet moves could spark fresh tensions. Back in November, Fintan Ryan at Goodbody flagged asset sales as still being “part of the strategy” to lower leverage. Chris Beckett from Quilter Cheviot suggested a dividend cut might ease pressure over time, though it could weigh on shares initially. Reuters

The downside risk remains: a drawn-out U.S. slowdown, ongoing discounts in spirits, or another weak spell in China could push companies to make harder calls on pricing, spending, and returns.

Diageo’s interim results drop on Feb. 25, putting focus on whether the company will revise guidance or signal changes in capital allocation, especially dividends.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Aviva share price rebounds in early London trade after Friday’s slide — what’s next for AV.L
Previous Story

Aviva share price rebounds in early London trade after Friday’s slide — what’s next for AV.L

Reckitt share price slides in London: what RKT investors are watching ahead of the special dividend vote
Next Story

Reckitt share price slides in London: what RKT investors are watching ahead of the special dividend vote

Go toTop